Gastric cancer (GC) represents a worldwide problem being the third leading cause of cancer-death [1]. Most patients present with an advanced stage at diagnosis and require systemic treatment. While chemotherapy has shown a limited effect [2], molecularly driven therapies are urgently needed. In the article that accompanies this editorial, Yoon et al. [3] report negative results of a randomized, placebo-controlled, double-blind phase II study with ramucirumab, the fully human monoclonal antibody directed to the vascular endothelial growth factor receptor 2 (VEGFR-2). These results contrast with the demonstrated mild but positive effects of antiangiogenic therapies in GC [4–8]. The large number of oesophageal cancer (EC) patients included in this study (48%), and the high rate of premature...

Article PDF first page preview

Article PDF first page preview
Article PDF first page preview
You do not currently have access to this article.